Press Releases

Many of the provisions included in this budget proposal would jeopardize the continued biotech research and development that is necessary to find cures and breakthrough medicines for patients living with debilitating and life-threatening diseases. 

The Biotechnology Industry Organization (BIO) today presented Sen. Debbie Stabenow (D-Mich.) the BIO Legislator of the Year award

Discover International Programming at BIO’s 2014 World Congress on Industrial Biotechnology

Celebrating its 11th annual World Congress on Industrial Biotechnology, the Biotechnology Industry Organization (BIO) is today announcing this year’s breakout program, which include new sessions on the use of industrial biotechnology in personal care and common household products.

BIO press release anouncing the publication of the 2014 International Service for the Acquisition of Agri-Biotech Applications (ISAAA) report.  

Bill would spur capital formation for small public companies

The Biotechnology Industry Organization (BIO), along with 28 other ag and food organizations, announced today the formation of the Coalition for Safe Affordable Food (www.CFSAF.org). 

BIO thanked Senate Agriculture Committee Chairwoman Debbie Stabenow (D-Mich.) and Ranking Member Thad Cochran (R-Miss.) on final passage in the Senate of the Federal Agriculture Reform and Risk Management Act of 2013. BIO also thanked the energy title’s many champions in the Senate, including Sens. Roy Blunt (R-Mo.), Al Franken (D-Minn.), Charles Grassley (R-Iowa), Tom Harkin (D-Iowa), and Amy Klobuchar (D-Minn.).

Patients Should Be Informed if Doctor's Prescription Changed

BIO today thanks House champions of the Farm Bill energy title and congratulates them on final passage of the bill.

The Environmental Protection Agency (EPA) lacks authority to waive the overall 2014 volume requirements for the Renewable Fuel Standard, particularly when production and supply of advanced biofuels continues to grow, BIO emphasized in official comments filed today.

The Farm Bill conference report contains significant funding for renewable energy programs, allows renewable chemical technologies to access the programs, and supports purpose grown energy crops.

Updated Convention features include new session formats, premier networking opportunities and improved programming

Thirty-one Senators and 31 Congressmembers signed letters to EPA Administrator Gina McCarthy protesting the proposed rule for the 2014 Renewable Fuel Standards.

BIO announced plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 16th annual BIO CEO & Investor Conference.

BIO and WBBA commend the Washington State House and Senate for continuing to advance legislation designed to create a pathway for the substitution of interchangeable biologic medicines.

Spending plan would enable the FDA to access $85 million in sequestered user fees

BIO expresses strong support for the “Bipartisan Congressional Trade Priorities Act of 2014”, which was issued by a bipartisan group of leaders from the Senate Finance and House Ways and Means Committee last week. 

Nature Biotechnology published a peer-reviewed paper co-authored by the BIO Industry Analysis and BioMedTracker (BMT) highlighting results of a study showing that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2011 is near one in 10.

BIO today echoed the request by the Secretaries of Energy, Agriculture and the Navy for funding and transfer authority for the Department of Energy to participate in the public-private partnership to commercialize biofuels for military use.

More than 140 Companies Expected to Present Their Story to Top Public and Venture Capital Investors

BIO applauds the House of Representatives for passing a bipartisan budget deal, which raises discretionary budget caps, which should provide the Food and Drug Administration  with complete access to its user fees for FYs '14 and '15. 

Hastings highlighted the need to advance the regulatory environment so that it fosters biopharma innovation. Among his recommendations, Hastings emphasized the need to eliminate the sequestration of industry user fees and expedite drug development for serious and life-threatening diseases by expanding the existing Accelerated Approval pathway and by facilitating the new Breakthrough Therapy Designation process.